Mukka Proteins Q1 FY27 Results (NSE: MUKKA)

· Analysis by Alpha Inflection

Signal: Margin expansion

The read

The key inflection is the return to a 10.1% consolidated EBITDA margin from 8.0% in Q1FY26 alongside 186.7% revenue growth, but gross margin compressed about 220bps and group PAT of ₹188.88 million remained below standalone PAT of ₹194.07 million as subsidiaries and joint ventures dragged earnings.

Mukka Proteins Q1 FY27 key financials
MetricValueYoYQoQ
Revenue₹489.65 Cr186.7%+28.6%
EBIT₹44.78 Cr223.3%
Net profit₹18.89 Cr1142.8%
EPS₹0.631160.0%
EBIT margin10.1%

P&L walk

Consolidated revenue increased to ₹4,896.54 million (+186.7% YoY, +28.6% QoQ), EBITDA rose to ₹495.7 million (+189.7%) and margin reached 10.1%, while gross margin compressed 220bps as inventory-related costs increased relative to revenue; finance costs rose 49.0% YoY and subsidiaries and joint ventures diluted group PAT.

Segments

Outside India drove the group with ₹4,140.68 million of revenue, +170.9% YoY, while within-India revenue grew faster at +405.7% but remained smaller at ₹607.36 million; consolidated PAT of ₹188.88 million was below standalone PAT of ₹194.07 million because reviewed subsidiaries reported ₹7.81 million of net loss and joint ventures reported ₹9.51 million of share loss.

Key positives

Key concerns

View original filing

Research and educational content only. Not investment advice.